Lv71
3260 积分 2022-01-11 加入
复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识
3个月前
已完结
局部晚期头颈部鳞癌治疗进展
3个月前
已完结
头颈部鳞状细胞癌免疫新辅助治疗的现状与展望
3个月前
已完结
头颈部鳞状细胞癌免疫治疗研究进展
3个月前
已完结
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
5个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
8个月前
已完结
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
8个月前
已完结
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study
8个月前
已完结
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
8个月前
已完结
皖公网安备34019202002308
